BI Asset Management Fondsmaeglerselskab A S Boosts Stake in Humana Inc. (NYSE:HUM)

BI Asset Management Fondsmaeglerselskab A S boosted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 95.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,400 shares of the insurance provider's stock after purchasing an additional 2,636 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Humana were worth $1,370,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FPC Investment Advisory Inc. acquired a new position in Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC acquired a new position in shares of Humana during the fourth quarter worth $30,000. LFA Lugano Financial Advisors SA increased its holdings in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management bought a new position in shares of Humana in the 4th quarter valued at $33,000. Finally, Atwood & Palmer Inc. boosted its holdings in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after acquiring an additional 60 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Down 0.5 %

Shares of NYSE:HUM traded down $1.37 during midday trading on Monday, hitting $263.03. 201,547 shares of the company's stock were exchanged, compared to its average volume of 1,741,121. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a market cap of $31.75 billion, a PE ratio of 26.44, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The stock has a 50 day moving average price of $266.35 and a 200-day moving average price of $270.81.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.35%. The ex-dividend date of this dividend is Friday, June 27th. Humana's dividend payout ratio (DPR) is presently 35.58%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HUM. Piper Sandler lifted their price target on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research note on Wednesday, January 15th. Barclays lifted their target price on shares of Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a research report on Friday, April 11th. Mizuho upped their price target on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Truist Financial raised their price target on shares of Humana from $290.00 to $325.00 and gave the company a "hold" rating in a research note on Friday, April 11th. Finally, JPMorgan Chase & Co. decreased their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $284.90.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.